Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy
- 1 March 1997
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 51 (3), 880-887
- https://doi.org/10.1038/ki.1997.124
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Monocyte/macrophage response to β2-microglobulin modified with advanced glycation end productsKidney International, 1996
- Glycation of Human .beta.2-Microglobulin in Patients with Hemodialysis-Associated Amyloidosis: Identification of the Glycated SitesBiochemistry, 1994
- Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPDKidney International, 1994
- β2-Microglobulin Modified with Advanced Glycation End Products Induces Interleukin-6 from Human Macrophages: Role in the Pathogenesis of Hemodialysis-Associated AmyloidosisBiochemical and Biophysical Research Communications, 1994
- Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failureThe Lancet, 1994
- Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.JCI Insight, 1993
- Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products.JCI Insight, 1993
- Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy.The Journal of Experimental Medicine, 1991
- Role of Oxidative Stress in Development of Complications in DiabetesDiabetes, 1991
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988